AGM - Chair address and CEO presentation
Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 2.00pm today.
Download: AGM - Chair address and CEO presentation (pdf file, 1MB)
The Australian: Cancer trial results prove good medicine for biotech's stocks
The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."
Targeted DEP™ outperforms leading treatments in ovarian cancer model
Melbourne, Australia; Starpharma today announced that treatment with its novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.
Starpharma receives $3.4M R&D tax incentive refund
Starpharma today announced it has received the anticipated $3.4M of R&D tax incentive refund related to FY15 expenditures.
Starpharma to present at Bio-Europe® conference
Starpharma today announced that it will present at the Bio-Europe® conference in Munich which is being held this week. At the conference Starpharma will also be conducting partnering discussions for VivaGel® BV and DEP™ with pharmaceutical companies.